Kornimate/medical-research-clean huggingface dataset:
using the objective physiological parameters to test tcm syndrome in sub-health subjects

Conditions: Health Status

Summary: background: suboptimal health status (shs) is a dynamic state potential clinical stage or prior psychosomatic disease stage during which people have not been diagnosed with a disease, but they have risk factors for illness and have tendency to develop diseases. the term refers to an existing condition of ill health that could lead to a pathologic condition but could also be eliminated, enabling the individual in question to return to a state of good health. traditional chinese medicine (tcm) emphasizes the importance of health care and the idea that preventive treatment for diseases is superior to curative treatment. therefore, early tcm-based intervention can improve the health status of people with shs. people with shs often experience such nonspecific symptoms as fatigue; such symptoms are typical of shs from the perspective of tcm. the present study investigated people with shs and fatigue as their primary symptom. all enrolled participants completed a physical questionnaire, after which their physiological parameters were monitored using a cloud physiological signal monitoring system to investigate correlations with tcm patterns. methods: the participants first completed a body constitution questionnaire, the who quality of life questionnaire, the shsq-25 questionnaire, the epworth sleepiness scale, and the pittsburgh sleep quality index, and subsequently underwent sphygmography to determine their pulse patterns. analyses of pulse waves were presented in relation to the spectral energy ratio (ser), and ser10 scores represented subtle changes in internal organ blood flow; 13-50-hz spectrum analysis for pulse delineated any flow energy deviation in organs.


Eligibility criteria:
inclusion criteria: * fatigue combined with one or more of the following symptoms of insomnia and higher dreaming frequency, irritability and short temperedness, forgetfulness, chest tightness, lack of concentration, or loss of memory (assessed using the suboptimal health status questionnaire-25 \[shsq-25\]). * body mass index (bmi) between 25 and 30 kg/m2. * resting blood pressure measured as 130-139/80-89 mmhg on more than three occasions in 1 week. * shsq-25 score of ≧35 exclusion criteria: * individuals diagnosed as having a chronic condition by western medicine, including hypertension, diabetes, chronic hepatitis, chronic kidney disease, chronic hyperlipidemia, and coronary heart disease. * individuals diagnosed as having a mental illness by western medicine. * individuals diagnosed with cancer.

Keywords: subhealth obese hypertension sleep apnea syndrome fatigue tcm syndrome physiological signal monitor system
gene mutations and rescue in human congenital diaphragmatic hernia

Conditions: Congenital Diaphragmatic Hernia

Summary: congenital diaphragmatic hernia (cdh) occurs when the diaphragm, the muscle that separates the chest cavity from the abdominal cavity, does not form properly. when an opening is present in the diaphragm, organs that are normally found in the abdomen can move up into the chest cavity. the primary objective of this study is to generate information about the hereditary basis of congenital diaphragmatic hernia and abnormal lung development. our long-term goal is to identify ways to treat babies in utero with effective but safe drugs to speed up lung development before birth.

this study uses a combination of clinical, molecular biological, and developmental strategies to better understand the genetic basis of congenital diaphragmatic hernia. ongoing projects at massachusetts general hospital include identification of novel genes affecting diaphragm and lung development in a) mouse models using laser capture, microdissection, expression arrays, and statistical and bioinformatics analysis and b) human kindreds with multiple affected family members using linkage analysis and exome sequencing. research projects based at children's hospital boston include a) continued recruitment of a population of patients with congenital diaphragmatic hernia who are carefully phenotyped for entry into an extensive database, b) collection of biological samples belonging to the phenotyped cohort of patients, c) next-generation sequencing on candidate genes and d) molecular cytogenetic studies such as comparative genomic hybridization and subtelomeric fluorescence in situ hybridization. over 500 patients with congenital diaphragmatic hernia and their families have been recruited to date and efforts are ongoing to double this number. the investigators hope that the information gained through identifying the genes that contribute to congenital diaphragmatic hernia will provide the foundation for future efforts to develop effective interventions for the treatment of this disease.

Eligibility criteria:
inclusion criteria: all individuals affected with a congenital diaphragmatic hernia (cdh), or with a family history of cdh exclusion criteria: individuals with no personal or family history of a cdh

Keywords: genes genetic chromosome chromosome microarray
effectiveness of aerobic exercises and laughter yoga compared with yoga in anxiety/depression levels in breast cancer

Conditions: Breast Cancer Survivors

Summary: 90% of breast cancer survivors experience cancer-related fatigue which decreases the physical activity. moreover, due to the cancer treatments depression and anxiety will be happened. previous studies showed the effect of physical activity on reduction of depression and anxiety; therefore the aim of this study is to evaluate the effectiveness of aerobic exercises and laughter yoga compared with yoga in anxiety and depression levels in breast cancer survivors.

204 breast cancer survivors will be randomized to each of these three groups: group 1, 12 weeks aerobic exercises; group 2, 12 weeks of laughter yoga; and group 3, 12 weeks of yoga. to assess the effectiveness of these exercises in depression and anxiety levels, patients will complete the hospital anxiety and depression scale (hads) questionnaire before and after the 3-month exercise. for secondary outcomes, patients will complete the following questionnaires before and after the 3-month exercise: 36-item short-form survey (sf-36), minnesota living with heart failure questionnaire (mlhfq), insomnia severity index, beck's depression inventory-ⅱ (bdi-ⅱ), chalder's chronic fatigue syndrome, and five facet mindfulness questionnaire (ffmq). the effectiveness of the mentioned exercises in primary and secondary outcomes will be assessed using anova/ancova analysis by adjusting the baseline assessment. mean difference (md) and standardized mean difference (smd) with their 95% confidence interval (ci) will be reported to show the effectiveness of aerobic exercises and laughter yoga compared with yoga in different outcomes.

Eligibility criteria:
inclusion criteria: * patients aged between 20 to 65 years * patients with stage ⅰ-ⅲ of breast cancer * chemotherapy is completed at least six months before registration * lack of active participation in regular exercise programs exclusion criteria: * reluctance to cooperate and enter the study * do not complete the questionnaires correctly * have diseases such as severe heart failure (minnesota living with heart failure questionnaire score more than 50), severe valvular disease, coronary stenosis of the heart, and metastatic cancer * feel chest pain and dizziness during the exercise * patients currently receiving treatment * patients who do not have the physical ability to participate in the exercise * patients with mental health disorders that cannot participate in the exercise

Keywords: aerobic exercises laughter yoga yoga depression anxiety
practice based nutrition intervention

Conditions: Type 2 Diabetes

Summary: this study aims to test a dietary intervention for diabetes in a medical practice setting, with the aim of developing a model for diabetes care that can be used widely. the investigators hypothesize that a low-fat vegan diet will be effective for management of diabetes and will be feasible in a practice-based setting.

specific aim 1 tests the hypothesis that the nutrition intervention (low fat, low-gi vegan diet) improves glycemic control, body weight, plasma lipid concentrations, blood pressure, and indices of renal function in a within-group analysis. specific aim 2 tests the hypothesis that the nutrition intervention (low fat, low-gi vegan diet) is more effective than standard nutrition care for improving glycemic control, body weight, plasma lipid concentrations, blood pressure, and indices of renal function in individuals with type 2 diabetes specific aim 3 tests the hypothesis that a low-fat vegan diet is sustainable among individuals with type 2 diabetes for a 20-week period, with weekly classes, and in a follow-up period of one year with limited professional support. specific aim 4 tests the hypothesis that a low-fat vegan diet has an acceptability that is comparable to that of standard nutrition care among individuals with type 2 diabetes. specific aim 5 tests the hypothesis that the effects of the dietary interventions on a1c and body weight are reduced in individuals with the a1 allele of the taq1a and taq1b polymorphism

Eligibility criteria:
inclusion criteria: 1. a diagnosis of type 2 diabetes mellitus, as defined by a fasting plasma glucose concentration ≥126 mg/dl on 2 occasions or a prior physician's diagnosis of type 2 diabetes with the use of hypoglycemic medications for at least 6 months 2. male or female 3. a1c between 6.5% and 10.5% 4. age at least 18 years 5. ability and willingness to participate in all components of the study 6. willingness to be assigned to either a low-fat, vegan diet or to standard nutrition care 7. diabetes medications unchanged for 1 month prior to volunteering for the study 8. patient of dr. mark sklar exclusion criteria: 1. body mass index \>45 kg/m2 2. alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use 3. use of recreational drugs in the past 6 months (past drug use, if fully recovered, is not a criteria for exclusion) 4. pregnancy or plans to become pregnant 5. history of severe mental illness (with current unstable status) 6. likely to be disruptive in group sessions (as determined by research staff) 7. signs/symptoms of acute uncontrolled diabetes (including but not limited to polyuria, polydipsia, blurred vision, uncontrolled weight loss) 8. unstable medical status 9. already following a low-fat, vegetarian diet 10. an inordinate fear of blood draws 11. inability to maintain current medication regimen 12. lack of english fluency
a study to evaluate the safety and immunogenicity of the hepatitis a virus vaccine havpur in healthy young children

Conditions: Hepatitis A

Summary: this is a study to test whether vaccination with havpur junior against hepatitis a provides protection that is non-inferior to the protection afforded by vaccination with havrix 720 junior.


Eligibility criteria:
inclusion criteria: * a male or female between (and including) 18 months to 47 months of age. * written informed consent obtained from the parent/legal guardian of the subject. * free of obvious health problems as established by medical history and/or clinical examination before entering the study exclusion criteria: * seropositive for anti-hav antibodies (\>=10 miu/ml). * use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up. * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose (for corticosteroids, such as prednisone, or equivalent, \>=0.5 mg/kg/day. * inhaled and local steroids are allowed.) * planned administration/ administration of a measles containing vaccine within 4 weeks prior to and after the first or booster dose of study vaccine. * previous vaccination against hepatitis a. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * major congenital defects or serious chronic illness. * acute disease at the time of enrolment

Keywords: hepatitis a vaccination immunity
a study of the safety and efficacy of anacetrapib (mk-0859) among participants with hypercholesterolemia when added to ongoing statin therapy (mk-0859-022)

Conditions: Hypercholesterolemia

Summary: this study will evaluate the effects of anacetrapib on low-density lipoprotein-cholesterol (ldl-c) and high-density lipoprotein cholesterol (hdl-c) in participants with hypercholesterolemia when added to an existing statin therapy.


Eligibility criteria:
inclusion criteria: * if female, cannot be of reproductive potential * has been treated with an appropriate dose of statin for at least 6 weeks * coronary heart disease (chd) or other atherosclerotic vascular disease with multiple risk factors (including diabetes, metabolic syndrome) and/or high ldl-c/low hdl-c, or needing to meet a specific ldl-c/hdl-c goal exclusion criteria: * previously participated in a study with a cholesteryl ester transfer protein (cetp) inhibitor * homozygous familial hypercholesterolemia * severe chronic heart failure * uncontrolled cardiac arrhythmias, myocardial infarction (mi), percutaneous coronary intervention (pci), coronary artery by-pass graft (cabg), unstable angina, or stroke within 3 months * uncontrolled hypertension * uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins * active or chronic hepatobiliary, hepatic, or gall bladder disease * history of mental instability, drug/alcohol abuse within the past five years or major psychiatric illness inadequately controlled and unstable * history of ileal bypass, gastric bypass, or other significant condition associated with malabsorption * human immunodeficiency virus (hiv) positive * history of malignancy ≤5 years * donated blood products or has had phlebotomy of \>300 ml within 8 weeks or intends to donate 250 ml of blood products or receive blood products within the projected duration of the study * currently taking medications that are potent inhibitors or inducers of cytochrome p450 3a4 (cyp3a) (including but not limited to cyclosporine, systemic itraconazole or ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, st john's wort) or has discontinued treatment \<3 weeks prior * consumes more than 2 alcoholic drinks per day * currently participating or has participated in a study with an investigational compound or device within 3 months * receiving treatment with systemic corticosteroids or taking systemic anabolic agents
reimbursement study of continuous glucose monitoring in belgium

Conditions: Diabetes, Type 1

Summary: type 1 diabetes mellitus (t1dm) is an autoimmune disease caused by an immune mediated destruction of the pancreatic β-cells. once the pancreas has been depleted of a critical mass of β-cells the need for exogenous insulin therapy emerges. several methods exist to administer insulin. an alternative way to administer insulin is by means of continuous subcutaneous insulin infusions (csii) or insulin-pump therapy.the frequent execution of self-monitoring of blood glucose (smbg) accomplished by a capillary finger-stick test is essential in the management of diabetes, but this is very limited and also lacks information about rising or falling trends in the actual glycaemia. a solution for this is the use of a real-time continuous glucose monitoring (rt-cgm) device. contrary to smbg, rt-cgm measures glycaemia 24 hours a day, provides information about glucose direction and rate of change during multiple days a week. since september 2014, rt-cgm is reimbursed in belgium for a selected group of type 1 diabetic patients by means of a so-called "cgm convention". the main objective of the study is to evaluate the impact of real time continuous glucose monitoring reimbursement on real-life clinical care parameters of type 1 diabetic patients in belgium after 12 and 24 months.


Eligibility criteria:
inclusion criteria: * patients with t1dm included in the rt-cgm reimbursement system and followed in one of 17 diabetes centers. exclusion criteria: * patients who are not included in the rt-cgm reimbursement system.

Keywords: type 1 diabetes real-time continuous glucose monitoring observational study insulin pump belgium
non-linear multimodal microendoscopy for lung cancer pathology

Conditions: Lung Cancer

Summary: for this study the investigators are looking to do the following: 1. to characterize human lung lesions by nonlinear microscopy using ex vivo tissues. 2. to establish the first spectral/structural database for nonlinear optical microimaging of normal and abnormal lung tissue.

for this study the investigators are looking to do the following: 1. to characterize human lung lesions by nonlinear microscopy using ex vivo tissues. in particular, to investigate collagen content and ultrastructure with shg (second harmonic generation) microscopy, to characterize cell and nuclear morphology and lipid vesicle content with thg (third harmonic generation) and cars (coherent anti-stokes raman scattering) microscopy and to conduct spectroscopic and lifetime characterization of mpf (multiphoton fluorescence) signals in cancerous, benign, and normal tissues. 2. to establish the first spectral/structural database for nonlinear optical microimaging of normal and abnormal lung tissue, from which to generate diagnostic algorithms, both to optimize the operating parameters of planned nonlinear endoscopic imaging and to serve as the basis for nonlinear optical histopathology.

Eligibility criteria:
inclusion criteria: * age 18 years or older. * patients with confirmed or suspected lung cancer who require lobectomy as part of standard-of-care. exclusion criteria: * patients deemed on clinical grounds not to be medically fit for a lobectomy * patients where there is a high clinical suspicion of lymphoma (to avoid mixing the data sets). * patients unable to give informed consent
postoperative atrial fibrillation in cardiac surgery

Conditions: Post-operative Atrial Fibrillation

Summary: this multicenter observational study aims to investigate the incidence and identify risk factors associated with postoperative atrial fibrillation (poaf) in patients undergoing cardiac surgery at three medical centers in thailand. the study will examine patient characteristics, surgical factors, and anesthetic management practices that may contribute to the development of this common postoperative complication.

postoperative atrial fibrillation (poaf) is a common complication following cardiac surgery, with incidence rates reported between 15-30% after valve surgery and 18-74% after coronary artery bypass grafting. poaf typically occurs within 72 hours after surgery and is associated with increased morbidity, mortality, length of hospital stay, and healthcare costs. the society of thoracic surgeons has identified five major postoperative complications associated with cardiac surgery, including poaf, which can significantly affect patient outcomes. this multicenter observational study will examine the incidence and risk factors of poaf in cardiac surgery patients across three medical centers in thailand: srinagarind hospital at khon kaen university, northeastern thailand cardiac center, and surat thani hospital. the study will collect data on patient demographics, comorbidities, preoperative laboratory values, perioperative characteristics, surgical procedures (valve surgery, cabg, combined procedures), and postoperative complications. by identifying risk factors associated with poaf, this study aims to develop preventive strategies and improve management protocols for patients at high risk for this complication.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients undergoing cardiac valve surgery or coronary artery bypass grafting (cabg) procedures exclusion criteria: * patients undergoing aortic surgery * patients undergoing maze procedure * incomplete medical records * patients who required mechanical circulatory support before surgery * patients who died during surgery or within 3 days after surgery

Keywords: postoperative atrial fibrillation cardiac surgery
evaluation of platelet rich fibrin / biphasic calcium phosphate effect versus autogenous bone graft on reconstruction of alveolar cleft

Conditions: Alveolar Ridge Abnormality

Summary: p- maxillary alveolar cleft defects i- platelet-rich fibrin (prf) combined with biphasic calcium phosphate (bcp) c- autogenous bone graft o- outcome measure : bone height, bone volume, hospital stay, operation duration t- 6 months s- randomized controlled clinical trial this study aimed to answer a clinical question whether the use of platelet-rich fibrin (prf) combined with biphasic calcium phosphate (bcp), can be an alternative to autogenous bone graft in reconstruction of alveolar cleft defect in maxillary arch.

this study aimed to answer a clinical question whether the use of platelet-rich fibrin (prf) combined with biphasic calcium phosphate (bcp), can be an alternative to autogenous bone graft in reconstruction of alveolar cleft defect in maxillary arch

Eligibility criteria:
inclusion criteria: * patients suffering from maxillary alveolar cleft * patients' age 8 years and older exclusion criteria: * syndromic cases will be excluded * patients suffering from platelets disorders.

Keywords: alveolar cleft -platelet rich fibrin- calcium phosphate
model 20105 lead study

Conditions: Sick Sinus Node Syndrome

Summary: the purpose of this study is to evaluate the implant procedure and feasibility of a new lead developed to pace and sense the left chambers of the heart.


Eligibility criteria:
inclusion criteria: * subject has cardiac pacing indication for sinus node dysfunction (dual chamber pacemaker) * subject has signed and dated the study-specific informed consent form * subject is 18 years of age or older * subject is willing, able and committed to participate in baseline and follow-up and study procedures for the full length of the study exclusion criteria: * subject is indicated for biv pacemaker or icd * subject is pacing dependent * subject has a previous pacemaker system * subject has known coronary venous vasculature that is inadequate for lead placement * subject has unstable angina pectoris or has had an acute myocardial infarction (mi) within the last month * subject has had a coronary artery bypass graft (cabg) or percutaneous transluminal coronary angioplasty (ptca) within the past three months * subject is not in sinus rhythm at implant * subject has had a heart transplant (patients waiting for heart transplants are allowed in the study) * subject has known renal insufficiency that would prevent them from receiving an occlusive venogram during the implant procedure * subject is contraindicated for \<1mg dexamethasone acetate * subject is enrolled in any concurrent drug and/or device study that may confound the results of this study * subject has a terminal illness and is not expected to survive more than 6 months * subject is a pregnant woman or woman of childbearing potential not on adequate birth control. * subject is employed by medtronic or by the department of any of the investigators or is a close relative of any of the investigators. * legal incapacity or evidence that a subject cannot understand the purpose and risks of the study * subject meets exclusion criteria required by local law. * subject is unable to tolerate an urgent thoracotomy